At Trove Therapeutics, we are developing a novel therapeutic protein, called Therabron™ to address neglected and undertreated respiratory conditions. We are a privately held, clinical-stage, biopharmaceutical company. Therabron™ is based on a naturally occurring secretoglobin protein called SCGB1A1, CC10, CC16, CCSP, or uteroglobin, and is a potent anti-inflammatory agent.

Trove is developing three distinct products using different formulations of Therabron™ with different routes of administration for specific respiratory diseases impacting people from childhood through adulthood.

Trove Therapeutics’ biopharmaceutical product candidate is a proprietary preparation of recombinant human SCGB1A1 protein, , called Therabron™, which has potential clinical applications in several respiratory diseases.Learn More
Trove Therapeutics holds specialized expertise required for the creation, development and commercialization of Therabron™.Learn More
Trove’s experienced biopharmaceutical executives and professionals, the Management Team and Board of Directors, have the technical and business acumen to advance our development programs from the research bench to clinical practice.Learn More


Several respiratory and autoimmune diseases may be caused, at least in part, by a lack of sufficient native SCGB1A1 protein in patients. We are developing a pharmaceutical therapy to replace SCGB1A1 with the synthetic version (Therabron™) in respiratory diseases characterized by inflammation and pre-existing SCGB1A1 deficiency.


Secretoglobins are naturally occurring proteins produced in the body by Club Cells. They are some of the most abundant proteins secreted in the airways. Naturally occurring SCGB1A1 is the most abundant protein in the fluid that lines the respiratory tract in both the upper and lower lung, including the sinus cavities. Unlike many treatments that provide symptomatic treatment only, Therabron™ has the potential to impact the underlying disease process, or to help resolve inflamed airways in a wide range of respiratory conditions such as persistent sinusitis, bronchiolitis obliterans (a type of pulmonary fibrosis) in lung and hematopoitetic cell transplant recipients, and acute lung injury such as that due to smoke inhalation.

Three Phase 1 and 2 clinical trials with Therabron™ have been completed and Trove aims to perform a Phase 2 trial in adults with chronic sinusitis, who are knwon to lack sufficient native SCGB1A1 in their nasal epithelium. We are developing Therabron™ to replace native SCGB1A1 in an effort to potentially benefit a range of respiratory conditions characterized by inflammation and native SCGB1A1 deficiency.

Trove Therapeutics, Inc. is a Delaware biotechnology corporation headquartered in Rockville, Maryland.

The Statistics Are Truly Overwhelming

Our goal is to improve long-term health outcomes and in doing so, potentially reduce healthcare costs.

Number of Hospitalizations for Acute Lung Injury and Respiratory Failure Annually
Number of Lives COPD Claims Annually (Respiratory Failure)
Americans with Recurrent Acute and Chronic Sinusitis
Americans Affected by Bronchiolitis obliterans, a Type of Pulmonary Fibrosis in Lung and Hematopoietic Cell Transplant